Raj Rajagovindan

VP Voyager Therapeutics, Inc

Seminars

Tuesday 3rd February 2026
Panel Discussion: Deciphering the Landscape of Emerging Neurodegenerative Fluid Markers Beyond p-tau & α-Synuclein
9:00 am
  • GBA, LRRK2, and TREM2: Where do these emerging targets stand in terms of measurable, scalable biomarkers?
  • What should define a ‘clinically useful’ biomarker when translatability remains uncertain?
  • How do we ensure fluid biomarkers reflect causal disease biology rather than downstream noise?
Raj Rajagovindan, Vice President - Translational Medicine, Voyager Therapeutics, Inc- 14th Alzheimers & Parkinsons Drug Development Summit